Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 6753417
UspA1 and UspA2 antigens of Moraxella catarrhalis
expired -
US 6752987
Adenovirus encoding human adenylylcyclase (AC) VI
expired -
US 6750043
Viral vectors having reduced virulence
expired -
US 6750234
Methods for increasing leptin levels using nicotinic acid compounds
expired -
US 6749853
Combined methods and compositions for coagulation and tumor treatment
expired -
US 6748954
Drug release from polymer matrices through mechanical stimulation
expired -
US 6750026
Screening methods using ligands of the neutropeptide receptor HFGAN72
expired -
US 6747013
Therapy for cellular accumulation in chronic inflammatory diseases
expired -
US 6747003
Modified vitamin K-dependent polypeptides
expired -
US 6746672
Isolated bifidobacteria that produce siderophores which inhibit growth of lactococcus lactis
expired -
US 6746869
Electrospraying apparatus and method for coating particles
expired -
US 6746662
pH sensitive MRI contrast agents
expired -
US 6747129
Target of RNAIII activating protein(TRAP)
expired -
US 6743607
Production of complex carbohydrates
expired -
US 6743936
Composites made using functionalized nanoparticles
expired -
US 6740751
Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells
expired -
US 6740320
Recombinant P53 adenovirus methods and compositions
expired -
US 6740493
Bone precursor cells: compositions and methods
expired -
US 6740744
VMP-like sequences of pathogenic borrelia
expired -
US 6737059
Methods of inhibiting inflammatory processes and alleviating symptoms associated with multiple sclerosis
expired -
US 6737052
Induction of programmed cell death by N5 gene
expired -
US 6730677
Benzofurazan compounds which enhance AMPA receptor activity
expired -
US 6730307
Anti-cryptosporidium parvum preparations
expired -
US 6730301
MCP-1 receptor antibodies
expired -
US 6730777
Cystic fibrosis gene
expired -
US 6730659
Antimicrobial peptides and methods of use thereof
expired -
US 6723548
DNA repair polypeptides and methods of use
expired -
US 6723329
Use of parapox B2L protein to modify immune responses to administered antigens
expired -
US 6723338
Compositions and methods for treating lymphoma
expired -
US 6723497
Therapeutic platelets and methods
expired -
US 6719969
Treatment of liver disease and injury with CXC chemokines
expired -
US 6720344
Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants
expired -
US 6719983
VMP-like sequences of pathogenic Borrelia
expired -
US 6720355
Sodium dodecyl sulfate compositions for inactivating prions
expired -
US 6720180
Wounded epithelium-specific transcript
expired -
US 6716825
Phosphonate compounds
expired -
US 6717030
Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
expired -
US 6716410
Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
expired -
US 6716423
Recombinant neospora antigens and their uses
expired -
US 6717017
Total synthesis of antitumor acylfulvenes
expired -
US 6716877
Method to treat chronic heart failure and/or elevated cholesterol levels
expired -
US 6713062
Acinetobacter outer membrane protein and gene sequence compositions and methods
expired -
US 6713078
Retrocyclins: antiviral and antimicrobial peptides
expired -
US 6709830
Methods for modulating the activation of a lymphocyte expressed G protein coupled receptor involved in cell proliferation, autoimmunity and inflammation
expired -
US 6709645
Synthesis of labeled metabolites
expired -
US 6710073
Drugs to improve synaptic transmission
expired -
US 6709858
Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
expired -
US 6706686
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory